Therefore, they concluded that since the expression of CD68 or CD163 is associated with an adverse outcome in patients treated with R-CHOP, double staining for CD68 and CD163 may be a better method of predicting outcomes of DLBCL [60]. This evidence concerns the gene CD163 and diffuse large B-cell lymphoma.